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Summary We examined loss of heterozygosity (LOH) for two loci on chromosome 17p (D17S5 and TP53),
and erbB-2 gene amplification, in primary breast cancers from 67 Brazilian patients. We identified two distinct
regions of LOH on chromosome 17p, one spanning TP53 and the other a more telomeric region (D17S5).
Based on a short-term follow-up, Kaplan-Meier analyses of patients' disease-free survival showed that
patients with LOH for D17S5, but retaining heterozygosity for TP53, were at higher risk of recurrence
(P = 0.007) than those who retained heterozygosity for D17S5. Bivariate analyses indicated that patients with
LOH for D17S5 alone had an increased risk of recurrence (hazard ratio = 7.2) over patients with erbB-2
amplification (hazard ratio = 3.7), when compared with patients with neither alteration (hazard ratio = 1.0).
Further, lymph node-positive patients whose tumours had both LOH for D17S5 and erbB-2 gene amplification
had a higher risk of recurrence than patients whose tumours had neither of these genetic alterations. Our data
confirm previous reports of a putative tumour-suppressor gene, distinct from TP53, on distal chromosome 17p
which is associated with breast cancer. They further suggest that LOH for loci in this region may provide an
independent indicator to identify patients with poor prognosis.
Several tumour-suppressor genes that may contribute to
breast cancer tumorigenesis are located on chromosome 17,
including NM23 (Leone et al., 1991), the BRCAJ gene
(17ql2-q23) (Hall et al., 1990; Easton et al., 1993), the TP53
gene (17pl3.1) and at least two other putative tumour-
suppressor genes not yet defined (Coles et al., 1990; Sato et
al., 1990; Anderson et al., 1992; Jacobs et al., 1993).
Loss of heterozygosity for loci on chromosome 17p has
been reported in 40-60% of sporadic breast carcinomas
(Mackay et al., 1988; Cropp et al., 1990; Devilee et al., 1991;
Andersen et al., 1992). Frequently, these genetic alterations
include the tumour-suppressor gene TP53. Mutations of this
gene have been identified in 20-40% of sporadic primary
breast tumours (Coles et al., 1992; Mazars et al., 1992) as
well as in the germline of some patients with Li-Fraumeni
syndrome, an inherited cancer syndrome associated with
breast cancer (Malkin et al., 1990). However, the frequency
of TP53 point mutations in breast tumours is significantly
less than the frequency of LOH detected for loci on distal
chromosome 17p (Chen et al., 1991; Mazars et al., 1992).
Further, Coles et al. (1990) have demonstrated two indepen-
dent regions of allelic loss on chromosome 17p in breast
tumours, one spanning TP53 and the other involving a more
telomeric region, implying the existence of another tumour-
suppressor gene distal to TP53.
Previous studies correlating chromosome 17p LOH with
clinicopathological variables in breast cancer have generally
failed to distinguish between events at TP53 and at the more
distal locus (B0rrensen et al., 1990; Cropp et al., 1991; Varley
et al., 1991). There have been two reports of an association
between LOH in the telomeric region of chromosome 17p,
but not at TP53, and lymph node status (Andersen et al.,
1992; Takita et al., 1992). However, neither of these reports
correlated LOH for distal chromosome 17p with overall sur-
vival or disease-free survival.
In this study, we analysed a panel of unselected, primary
breast tumours from Brazilian patients for LOH at loci on
chromosome 17p and for amplification of the erbB-2
oncogene. These parameters were then evaluated singly and




Samples of human primary breast carcinoma and adjacent
normal tissue from 29 premenopausal and 38 post-
menopausal females were obtained at the A.C. Camargo
Hospital, Sao Paulo, Brazil. The age of the patients at the
time of operation was 30-82 years. The median follow-up
time for all patients was 29 months (range 1-52 months).
Tumour samples were dissected to remove residual normal
tissue before freezing and storage in liquid nitrogen. The
largest diameter of the tumour was recorded. The number of
lymph node metastases was determined by microscopic
examination of an average of 24 lymph nodes per patient.
Haematoxylin and eosin-stained sections of fixed tissue were
used to determine tumour type. All patients were classified
according to the WHO Histological Typing of Breast
Tumours (WHO, 1982). Tumours studied include 60 infil-
trating ductal carcinomas, four infiltrating lobular car-
cinomas and three medullary carcinomas. The clinical stage
of the patients was determined according to the UICC TNM
(tumour, nodes, metastases) staging system (UICC, 1978). All
patients were submitted to radical mastectomy (modified or
Halstead type). Subsequent adjuvant systemic treatments
were not considered in our survival statistical model since use
of adjuvant therapy could have reflected the physician's
judgement with respect to the overall prognosis in each case,
precluding evaluation of the true cause-effect relationship
attributable to therapy.
Oestrogen and progesterone receptor content were deter-
mined by charcoal-dextran methods as described previously
(Brentani et al., 1981).
DNA extraction
Tissue were pulverised to a fine powder using a Frozen
Tissue Pulverizer (Termovac), resuspended in lysis buffer
(10 mM Tris-HCl pH 7.6 1 mM EDTA and 0.6% SDS) con-
taining proteinase K (100 jig ml-') and incubated at 37°C
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overnight. High molecular weight DNA was extracted with
phenol-chloroform and precipitated with ethanol containing
0.3 M sodium acetate.
Southern and dot-blot analyses
DNAs from normal and tumour tissue (10 ,ug) were digested
with TaqI for 6-12 h at 65°C according to the manufac-
turer's specifications (Pharmacia, NJ, USA). Digested DNA
samples were separated by electrophoresis on 0.8% agarose
gels and transferred to nylon membranes.
For dot-blot analysis, dilutions containing 10.0-0.3125 fig
of DNA from each sample were alkali denatured and applied
to Hybond N filters using a dot-blot apparatus (Gibco-
BRL).
Chromosome 17 probes YNZ22.1 (D17S5) (Nakamura et
al., 1988) and the 1.6 kb EcoRI fragment of erbB-2 cDNA
were labelled by random oligonucleotide priming (Feinberg
& Vogelstein, 1983).
Southern and dot blots were hybridised as previously de-
scribed (Mulligan et al., 1990). After autoradiography dot-
blot filters were stripped of probe and rehybridised using a
,-actin probe.
The intensity of the hybridisation signal was determined by
quantitative densitometry using a Joyce Loebl Chromoscan
3. The degree of erbB-2 amplification was determined by
comparing tumour and normal densitometric scans. A
tumour was considered positive for erbB-2 amplification if it
had a 3-fold greater signal intensity than the normal tissue.
Tumours were classified as having 3- to 5-fold or >5-fold
amplification. Hybridisation with a P-actin probe was used tQ
correct for differences in DNA loading.
Polymerase chain reaction (PCR) analysis ofmicrosatellites
LOH for TP53 was analysed by PCR using primers for
microsatellite polymorphisms (Futreal et al., 1991). PCR
reactions were performed in 25pl volumes using 50ng of
genomic DNA as described by Futreal et al. (1991). The
products were diluted 1:2 in 90% formamide, 10 mM EDTA,
0.3% bromophenol blue, 0.3% xylene cyanol, boiled for
5 min and resolved on a 6% denaturing polyacrylamide gel.
Alleles were detected by autoradiography of dried gels using
Kodak X-Omat XAR film for 4-48 h at - 70°C.
Statistical methods
Analyses of statistical significance between the genetic events
examined and the clinicopathological characteristics of the
patients were performed by the chi-square test. For these
analyses, patients were divided into categories for the
clinicopathological characteristics based on the following
points: age <50 years or > 50 years; tumour size <4 cm or
>4 cm; tumours that were oestrogen receptor negative
(< 10 fmol mg-' protein) or positive (>10 fmol mg-' pro-
tein); tumours that were progesterone receptor negative
(<20 fmol mg-' protein) or positive (>20 fmol mg' pro-
tein); patients lymph node negative or positive; and early-
stage tumours (stages I or II) or advanced-stage tumours
(stages III or IV).
Two statistical methods were used to assess the prognostic
significance of LOH for D17S5 and TP53 in the group of
patients analysed. Short-term follow-up disease-free survival
curves were calculated based on the Kaplan-Meier product
limit technique (Kaplan & Meier, 1958). Hazard ratios were
calculated using the proportional hazard model as described
by Cox (1972). Regression analyses were performed with
microcomputer programs as previously described (Marques
et al., 1990).
Results
Sixty-seven paired normal and breast tumour samples were
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Figure 1 Allele losses on chromosome 17p in 27 primary breast tumours informative for both TP53 and D17S5. Group 1 includes six
tumours with LOH for D17S5 and TP53; group 2 includes three tumours with LOH for TP53 but retaining heterozygosity for D17S5;
group 3 includes seven tumourswith LOH forD17S5 butretaining heterozygosity forTP53; andgroup4includes 11 tumours thatretain
heterozygosity for both loci. *, LOH; 0, heterozygosity retained. N, normal tissue DNA; T, tumour tissue DNA.756 M.A. NAGAI et al.
Table I Loss ofheterozygosity on Dl7S5 in 42 informative primary breast cancerpatientscompared withclinicopathological characteristics,
steroid hormone receptors and erbB-2 gene amplification
DI7SS (TP53 not considered) TP53 no lossc
Characteristic Category LOH (18) No loss (24)a P valueb LOH (7)d No loss (JJ)e P valueb
Age <50 years 7 8 2 6
>50 years 11 16 0.71 5 5 0.28
Clinical stage I 0 1 0 1
II 7 9 3 4
III 9 10 4 4
IV 2 2 0.82 0 0 0.64
Tumoursize <4cm 9 14 4 7
>4cm 9 9 0.49 3 4 0.78
Nodal status Negative 6 8 4 5
Positive 12 16 1.00 3 5 0.77
ER' Negative 3 6 1 1
Positive 15 16 0.53 6 10 0.73
PR' Negative 10 11 3 6
Positive 8 10 0.73 4 5 0.63
erbB-2 Single copy 12 15 4 6
Amplification 6 9 0.78 3 5 0.91
aSomeoftheclinicalinformationcouldnotbeobtained forall cases.bChi-square.cTumoursinformativeforD17S5 andTP53.dTumourswith
D17S5 LOH only. eTumours that retained heterozygosity for F17S5 and TP53. 'Steroid hormone receptors: ER(oestrogen receptor) negative,
10 fmolmg-' protein; positive, >10fmolmg-' protein; PR (progesterone receptor), negative, <20ffmolmg-' protein; positive,
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Figure 2 Kaplan-Meier curves for disease-free survival in
primary breast cancer patients, stratified according to LOH for
D17S5. D17S5 no loss = tumours retaining heterozygosity for
D17S5 and for TP53 (n = 14); D17S5 loss = tumours with LOH
for D17S5, but retaining heterozygosity for TP53 (n = 7). D17S5
no loss versus D17S5 loss, P = 0.007.
17. Allelic loss was detected in 23 of 50 tumours informative
(heterozygous) for at least one of these loci. The prevalence
of LOH was 43% at D17S5 (18 losses out of 42 informative
cases) and 28% at TP53 (10 losses out of 36 informative
cases).
Twenty-seven patients were constitutively heterozygous for
both D17S5 and TP53. These patients were divided into four
groups based on whether they lost alleles at D17S5, TP53,
neither or both loci (Figure 1). By comparing the allele loss
patterns in these groups we were able to define two distinct
regions ofallele loss on chromosome 17p, one spanning TP53
and the other a more telomeric region.
To assess the significance of allele losses on chromosome
17p in the development of primary breast cancer, we com-
pared the clinicopathological characteristics (age, tumour
size, steroid hormone receptors, lymph node status, clinical
stage) of the patients with LOH for either D17S5 alone
(group 3) or TP53 alone (group 2) with those of patients who
were informative but showed no LOH at either locus. No
significant associations were found for D17S5 (Table I). As
group 2 contained only three patients, a similar comparison
was not performed.
A Kaplan-Meier analysis of disease-free survival showed
that patients whose tumours had LOH for D17S5 alone
(group 3) had a significantly shorter (P = 0.007) disease-free
interval than patients who were informative but had no LOH
at this locus (groups 2 and 4) (Figure 2).
Since group 2 contained only three patients, it was not
possible to evaluate the prognostic value of TP53 allelic
losses alone in these patients. Kaplan-Meier analysis of
disease-free survival showed that patients in group 1 also had
a shortened disease-free interval, similar to that of patients
with LOH for D17S5 alone. This effect might have been due
to losses at TP53 or at the more distal tumour-suppressor
gene locus.
erbB-2 gene amplification was examined in the 42 cases
informative for D17S5. Fifteen cases (36%) had amplification
of erbB-2 sequences. Representative examples of tumours
with erbB-2 gene amplification are shown in Figure 3. The
amplification was 3- to 5-fold in 11 cases and >5-fold in
four cases.
To assess the relative utility of LOH at D17S5 and erbB-2
amplification as prognostic indicators, we analysed disease-
free interval with respect to these genetic events. Kap-
lan-Meier analysis showed that patients with LOH for
D17S5 had a poor prognosis irrespective of erbB-2 gene
amplification (P = 0.04). Patients with both LOH for D17S5
and erbB-2 amplification had the worst prognosis (P = 0.01)
(Figure 4).
A combined analysis of the effect of LOH at D17S5 and
amplification at erbB-2 (Table II) showed that either event
increased the risk of recurrence, and the risk was the
greastest for patients whose tumours had undergone both
events (hazard ratio = 7.2). This effect was increased in
patients whose lymph nodes were positive (hazard
ratio = 13.2).
Discussion
Our data are consistent with previous reports of two distinct
regions of allele loss on chromosome 17p, one encompassing
TP53 and the other more distal. In accordance with previous
reports on sporadic breast cancer, the frequency of LOH
observed for the telomeric region of chromosome 17p was
higher than that observed for TP53 (Coles et al., 1990; Sato
I17p ALLELE LOSS AND BREAST CANCER PROGNOSIS 757




Categories Crudeb P value nodal statusc P value
D17S5 no loss/single copy erbB-2 1.Od 1.0
D17S5 no loss/amplification erbB-2 3.7 3.3
D17S5 LOH/single copy erbB-2 7.2 5.0
D17S5 LOH/amplification erbB-2 6.8 0.029e 13.2 0.010
aCoxproportional hazardsmodel.bHazard ratioconsidering thewholepopulation, negativeand positive
patients for lymph node status. CHazard ratio considering only patients lymph node positive. dReference
category, patientswithoutanyofthegeneticalterationsexamined.ePatientswith LOHatD17S5anderbB-2























Figure 3 erbB-2 gene amplification in the tumours informative for
D1I7S5. Southemn and dot-blot analyses were performed as described
in Materials and methods. Patient 92 shows D17S5 no loss and
erbB-2 single copy; patient 01 shows D1I7S5 no loss and 3 to 5-fold
erbB-2 amplification; patient 69 shows DI17S5 allelic loss and erbB-2
single copy; and patient 28 shows DI17S5 allelic loss and erbB-2
> 5-fold amplification. N, normal tissue DNA; T, tumour tissue
DNA.
et al., 1990; Andersen et al., 1992). Recent studies in breast
cancer (Cropp et al., 1990; Andersen et al., 1992) and in
astrocytomas (Saxena et al., 1992) using a probe for locus
D17S34, which is telomeric to D17S5, have suggested that
the minimal region of LOH, and thus the location of a
put.ative tumour-suppressor gene lies between D17S5 and
D17S34.
If there is another tumour-suppressor gene, distinct from
TP53, on chromosome l7p, its role in breast cancer progres-
sion is unclear. Thompson et al. (1990) showed an associa-
tion between LOH for D17S5 and low levels of oestrogen
receptor, which is an indicator of poor prognosis.. However,
in agreement with other authors, our data showed that LOH
of D17S5 is not associated with clinicopathological prognos-
I D17S5 no lossi
ERBB2single copy n = 16
D17S5 no loss/
_lERBB2amplified n = 9
D17S5 no loss/
ERBB2single copy n = 12
D17S5 no loss/
ERBB2amplified n = 5
9 18 27 36 45 54
Time (months)
Figure4 Kaplan-Meiercurvesfordisease-free survivalinprimary
breast cancer patients, stratified according to LOH for D175
and/or erbB-2 amplification. Cox-Mantel log-rank analysis were
used to compare the D17S5 no loss/erbB-2 single-copy group with
patients with one or both genetic events. The P-values for these
comparisons were: D17S5 no loss/erbB-2 amplified, P= 0.062;
D17S5 loss/erbB-2 single copy, P= 0.04; D17S5 loss/erbB-2
amplified, P = 0.01.
tic variables such as age, tumour size, clinical stage or steroid
hormone receptor content (Cropp et al., 1990; Andersen et
al., 1992). Nor did D17S5 LOH correlate with lymph node
involvement, at present considered the most important prog-
nostic factor in breast cancer. However, patients with LOH
for D17S5, but retaining heterozygosity at TP53, had a
poorer prognosis than patients who retained heterozygosity
for D17S5.
Bivariate analysis of these data suggests that LOH at
D17S5 is a useful prognostic indicator in breast cancer,
independent of lymph node involvement. Up to one-third of
patients with lymph node-negative breast cancer without
adjuvant treatment relapse within 10 years (Early Breast
Cancer Trialists' Collaborative Group, 1992). Thus the
identification ofprognostic factors, independent of the lymph
node status, which can predict the course of the disease is
one of the most important goals in breast cancer research.
Our results suggest that LOH at loci in the telomeric region
of chromosome 17p might be one such independent factor.
This is consistent with studies showing an association
between LOH at D17S5 and high proliferative index in
breast tumours (Chen et al., 1991; Merlo et al., 1992).
We found no association between the occurrence of LOH
for D17S5 and erbB-2 gene amplification. This is consistent
with some reports (B0rrensen et al., 1990; Varley et al.,
1991), but not others (Sato et al., 1991; Knyazev et al., 1993).
Bivariate analyses suggested that LOH for DI7S5 and erbB-2
amplification are each independently associated with a poor
prognosis (Table II). Further, a combination of these two
genetic events and lymph node involvement provides an even758 M.A. NAGAI et al.
stronger indication of patient prognosis. Patients with LOH
for D17S5 alone or with LOH for D17SS (but not TP53) and
with erbB-2 amplification had a 7-fold increased risk of
recurrence over patients negative for these genetic events.
The risk of recurrence was increased 13-fold for lymph node-
positive patients with both genetic alterations over lymph
node-positive patients without these genetic changes. These
data suggest that the use of nodal status combined with the
analyses of genetic alterations might identify a group of
patients with more aggressive disease.
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